It's silly cheap.
As Dr Maiti said, "We should find out pretty early on." It's all about pushing those deep remissions back. His goal is to increase overall survival rate by 10-15%, " but if the trials follow the clinical data it could be much much higher. "
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-6
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.1¢ | 1.9¢ | $56.44K | 2.801M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1655923 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1520755 | 2 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |